»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ![0\m2~iv
]wc
'h>w
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 W{*U#:Jx1
es6!p 7p?
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© +A>>Ak|s
1.Antigen presenting cell£¨APC£© qm{(.b^
2.Activation induced cell death£¨AICD£© bd5\Rt
3.Chemokine N!
}p
4.Major histocompatibility complex£¨MHC£© l#Ipo5=
5.immunotolerance X6)-1.T&
h.l^f>,/
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© |Rd?s0u
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ bqWo*>l
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà mCb(B48]%X
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ V|13%aE_v
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ MX2]Q
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã aY@]mMz\
m9 o{y6_j*
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© 7/&i'y
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ Ye% e!
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ BiT
#bg
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ WK)hj{k
@a$_F3W
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ z6)b XL[f
t~]n"zgovz
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 ZP~Mg
z{f
u1a0w
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ c<bV3,
1.Antigenic determinant `?E|frz[
2.IgSF Zgy~Y0Di
3.MBL;¾¶ <+Eu.K&
4.chemokine fIe';a
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ cq+G 0F+H
6.TCR-CD3¸´ºÏÎï K)b@,/ 5
7.FADD£¨Fas-associated protein with death domain£© -w'
8.AIDS VaP9&tWXj
9.Tumor rejection antigen uDD{O~wF,
10.AICD 6$/Z.8
"o_s=^U
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ ,+2!&"zD
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© q8A ;%.ZLG
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ rebnV&-
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ 7[=\bL
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì d~#B,+
'3<T~t
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ de=){.7Y
B7x(<!B
s>J\h
רҵ¿Î ÃâÒßѧ B(|*u
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê M.FY4~
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell 21k,{FB'?
5. Fc¦Å receptor 6. Cytokine H 48YX(HI
¶þ¡¢ ÎÊ´ðÌâ
m^!Kthq
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 YCl&}/.pA
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ N\l|3~
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ lA{JpH_Y8s
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 &?[g8A
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠbG)EZ
A"tE~m;"7
m!5MGq~
E3hXs6P
LZtO Q__B)
C'~Eq3
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ lvAKL>qX
;n q"jm
_Z>ny&
רҵ¿Î ÃâÒßѧ %i6/=
'u
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê l{I.l
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen !'eh@BU;
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin 4wKQs&:
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test (`&SV$m
9. Hybridoma technic 10.Mitogen -zg 6^f_pW
11.Dentritic cell 12.Immunoproliferation gy1R.SN
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 8e5imei
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ wP7
E8'
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ?8qN8rk^+
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ %I=/
y
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ j.!5&^;u4
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ m\oxS;fxWi
z }Lf]w?
H:nO\]
}hE!0q~MfM
C|V5@O?;&
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 5)Z:J
Wf3{z
D~
[!C!R$AMa
רҵ¿Î ÃâÒßѧ !LQzf(s;
Ò»¡¢ Ãû´Ê½âÊÍ l,6' S8=
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï NoMlTh(O
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà ^M1jv(
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ {
e$@i
¶þ¡¢ ÎÊ´ðÌâ E9b>wP
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ n<P&|RTZ
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ d;,Jf*x\
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ c'XSs
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ s
?"\+b
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ B}P!WRNmln
Wv%F^(R7
$VjMd f
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ G5|'uKz2"
H?eG5
\irKM8]LJ
רҵ¿Î ÃâÒßѧ .AQTUd(_
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê OLWn0
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR E^Ch;)j|
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA vM-kk:n7f
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM P^ht$)Y
¶þ¡¢ ÎÊ´ðÌâ MskOPg
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ zJh!Q*
*
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ nTw:BU4jd
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ m;nH
v
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ :#
\jx
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ 2"k|IHs1
Q/J <$W*,
_,v>P2)
\F\xZ.r
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ o.Bbb=*rZ
T!pA$eE
hD7vjg&Z
רҵ¿Î ÃâÒßѧ %tPy]{S..
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê {d0
rUHP
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule 2f{a||
5. Autogous mixed lymphoyte reaction pc
QkJF
¶þ¡¢ ÎÊ´ðÌâ Q'hs,t1<
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ 5|`./+Ghk
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ (]VY==t~
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠAu{ b1n
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ 0-uVmlk=/
C1qlB8(Wh>
bA'N2~.,
)4hA Fy6l
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ -G'3&L4
D
9l |*E
epG =)gd=8
רҵ¿Î ÃâÒßѧ ;#8xRLW
k9NHdi7&2
r gi4>
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê k!x`cp
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance M"msLz
5. Delayed type hypersensitivity
aZ|S$-}
¶þ¡¢ ÎÊ´ðÌâ K$s{e0
79
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ Z^%HDB9^
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ {Q`Q2'@
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ H;DjM;be
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷ÓᣠNSR][h_
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠ6(Ntt
LY#V)f
%WX^']p
:o~]d
N] pw7S%
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ =rkW325O
6JRFYgI
q]s_ hWWv
רҵ¿Î ÃâÒßѧ %ZDO0P !/
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê A ^zd:h-
1. hypersensitivity 2. cluster of differentiation ZqjLZ9?q
3. adhesion molecules 4. supper antigen 5. split tolerance D^U?!S&4~
¶þ¡¢ ÎÊ´ðÌâ >McEuoZx9
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ >LPIvmT4D?
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ am7~
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ L!`PM.:9
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ 8,e%=7h_e
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ FMWM:
PR,8c
h2i1w^f
,pVe@ d'
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ m3&